Group 1 - The company approved a share repurchase plan using its own funds to buy back A-shares through the Shanghai Stock Exchange, with a maximum repurchase price of RMB 315 per share and a total repurchase amount between RMB 200 million and RMB 250 million [2] - The repurchase period is set for 10 months from the date of board approval [2] - The company will use the repurchased shares for employee stock ownership plans or equity incentives [2] Group 2 - As of December 31, 2025, the company has repurchased a total of 402,976 shares, accounting for 0.29% of the total share capital of 141,030,049 shares, with a total expenditure of RMB 99.923 million [3] - The highest purchase price was RMB 256 per share, while the lowest was RMB 235 per share [3] - The repurchase progress aligns with the established repurchase plan [4] Group 3 - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations in a timely manner [5]
证券代码:688617 证券简称:惠泰医疗 公告编号:2026-001